Kinaxo Biotechnologies has announced that it has entered a second collaboration with Takeda Pharmaceutical Company, Osaka, Japan.
Under the agreement, Kinaxo will apply its quantitative phosphoproteomics technology, Phosphoscout, to assist in research of drugs under development at Takeda.
This will allow Takeda to take early educated decisions on drug efficacy and safety.
Financial details of the agreement were not disclosed.
Phosphoscout enables quantitative analysis of cellular phosphoproteomes on a global scale.
Since signal transmission in eukaryotic cells is mainly regulated by reversible protein phosphorylation, comprehensive analysis of phosphoproteome modulation in response to drug treatment provides valuable insights into a drug's mode of action.
Furthermore, Phosphoscout can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug-response biomarkers in clinical trials.
Phosphoscout utilises mass spectrometry methods enabling unbiased quantification of approximately 15,000 phosphorylation sites in a single experiment.
Proprietary bioinformatic software tools are applied to visualise the drug's effects on cellular signal transduction pathway and help identify phospho-protein biomarkers.